Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS6005-R
- Development stage
- Preclinical
- Lead developer
- CStone Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CS6005-R is a next-generation small-molecule inhibitor of the RET (Rearranged during Transfection) tyrosine kinase, developed by CStone Pharmaceuticals. It is specifically designed to overcome resistance mechanisms that emerge following treatment with first-generation RET inhibitors, such as pralsetinib and selpercatinib. CS6005-R targets a broad spectrum of RET alterations, including wild-type RET, gatekeeper mutations (e.g., V804L/M), and solvent front mutations (e.g., G810R/S/C), which are common drivers in solid tumors like non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). The drug aims to provide a therapeutic option for patients who have progressed on initial RET-targeted therapies.
Beyond the preview
Go deeper on CS6005-R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS6005-R.